Abstract: Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Ring B, and Ring C are as defined herein, and wherein Ring B moiety and the NH—C(?X)—NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

Abstract: Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

Abstract: Compounds of Formula I: and salts thereof in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.

Abstract: The present disclosure is directed to a system and method for reducing ice or condensation that forms on a power component of a wind turbine during a power outage. The method includes determining an ambient temperature near the power component; providing one or more parameters of the power component; determining a down time of the power component for the power outage; determining a wait time for the power component to stay offline as a function of the ambient temperature, the one or more parameters, and the down time of the power component; and, heating the power component for the wait time before supplying power to the power component such that a surface temperature of the power component is raised above the ambient temperature. As such, the method prevents the power component from being energized when condensation or ice may be present.

Abstract: An oral care composition comprising (a) a silica abrasive having an average particle size of no greater than the diameter of a dentin tubule, or, alternatively 8 microns or less; (b) zinc citrate, (c) a bioadhesive agent, and (d) an anticalculus agent. The oral care composition can reduce or inhibit biofilm formation and/or dentinal hypersensitivity in an oral cavity.

Abstract: Described herein are compositions comprising combinations of metal salts, and methods of preparing and using the same.

Abstract: Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

Abstract: Described herein are compositions comprising combinations of metal salts, and methods of preparing and using the same.

Abstract: Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Ring B, and Ring C are as defined herein, and wherein Ring B moiety and the NH—C(?X)—NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

Abstract: Compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Ring B, and Ring C are as defined herein, and wherein Ring B moiety and the NH—C(?X)—NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

Abstract: Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

Abstract: Renewable energy power systems, DC to DC converters, and methods for operating energy storage systems are provided. A system includes a power converter having a DC bus, and an energy storage system coupled to the DC bus of the power converter. The energy storage system includes an energy storage device and a switching power supply coupled between the energy storage device and the DC bus of the power converter. The switching power supply includes a plurality of switching elements, and an energy storage device protection circuit coupled between the plurality of switching elements and the energy storage device, the energy storage device protection circuit including a solid state switch. The switching power supply further includes a fuse coupled to the energy storage device protection circuit.

Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R2, R2a, R3, R3a, and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases

Abstract: Renewable energy power systems, DC to DC converters, and methods for operating energy storage systems are provided. A system includes a power converter having a DC bus, and an energy storage system coupled to the DC bus of the power converter. The energy storage system includes an energy storage device and a switching power supply coupled between the energy storage device and the DC bus of the power converter. The switching power supply includes a plurality of switching elements, and an energy storage device protection circuit coupled between the plurality of switching elements and the energy storage device, the energy storage device protection circuit including a solid state switch. The switching power supply further includes a fuse coupled to the energy storage device protection circuit.

Abstract: The present subject matter is directed to a system and method for reducing ice or condensation that forms on a power component of a wind turbine during a power outage. The method includes determining an ambient temperature near the power component; providing one or more parameters of the power component; determining a down time of the power component for the power outage; determining a wait time for the power component to stay offline as a function of the ambient temperature, the one or more parameters, and the down time of the power component; and, heating the power component for the wait time before supplying power to the power component such that a surface temperature of the power component is raised above the ambient temperature. As such, the method prevents the power component from being energized when condensation or ice may be present.

Abstract: A power generation system may include a generator and a power converter coupled to the generator. The power converter may include a plurality of bridge circuits coupled in parallel. Each bridge circuit may be coupled to an inductor. In addition, the power converter may include a plurality of parallel shorting devices. The shorting devices may be coupled to the bridge circuits such that an impedance of the inductors is effectively coupled between the shorting devices and the generator.

Abstract: Compounds of Formula I: and salts thereof in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.

Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R2, R2a, R3, R3a, and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.

Abstract: A power generation system may include a generator and a power converter coupled to the generator. The power converter may include a plurality of bridge circuits coupled in parallel. Each bridge circuit may be coupled to an inductor. In addition, the power converter may include a plurality of parallel shorting devices. The shorting devices may be coupled to the bridge circuits such that an impedance of the inductors is effectively coupled between the shorting devices and the generator.

Abstract: A method of treating a disease or condition for which a JAK inhibitor is indicated in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, and particularly, a method for the treatment of various inflammatory diseases, particularly psoriasis, asthma and COPD.